Should your child start with an ADHD Stimulant or Non-Stimulant?

If your child has been diagnosed with ADHD more than likely their healthcare provider has discussed (or should have discussed) whether a stimulant or a non-stimulant would be the best fit for your child’s unique presentation.

Each of these two families have their own benefits and side effects making them a good fit for one child, and not a great fit for another.

How well do they actually work?

This is the question every parent wants answered, and there's a surprisingly clean answer thanks to a 2018 meta-analysis in Lancet Psychiatry by Cortese et al., which pooled 82 randomized trials and over 10,000 kids⁶.

It found these effect sizes on ADHD symptoms (vs. placebo) in pediatric populations. The more negative the number, the bigger the reduction in symptoms.

So below, amphetamine has the biggest negative number and atomoxetine has the smallest negative number.

In other words amphetamines are the most effective for treating ADHD, followed by methylphenidates, then guanfacine, then qelbree and finally atomoxetine, which isnt to say that atomoxetine is not effective, it is still a great choice for kids who have trialled and failed the other, more effective medications listed below.

Medication	Effect Size (SMD)	Class
Amphetamines	-1.02	Stimulant
Methylphenidate	-0.78	Stimulant
Guanfacine	-0.67	Non-stimulant
Viloxazine ER* (Qelbree)	~-0.45	Non-stimulant
Atomoxetine	-0.56	Non-stimulant

*Viloxazine (Qelbree) was approved after the Cortese meta-analysis; figures from its phase III trials⁷.

The pattern is consistent: stimulants win for treating ADHD, based on raw effectiveness, with amphetamines slightly ahead of methylphenidate in terms of how well they work, and the non-stimulants coming in second, and third, and fourth place.

The effect size of -1.02 for amphetamines is very strong. It means that the average kid with ADHD on amphetamines has fewer symptoms than ~84% of kids with ADHD who got a placebo. 

That’s why stimulant medications are the clear first-line treatment for ADHD, unless there are specific reasons to avoid them (e.g. family preference for a non stimulant, a child who is already low weight and/or has an eating disorder, or a child has severe anxiety which other stimulants have made worse, or if there is a tic disorder etc).

Furthermore, 65 to 80% of kids with ADHD will respond to the first stimulant medication tried. 85% respond if a second is tried when the first fails. Only around 15% won't see significant benefits from stimulants or can’t tolerate them and for these 15%, the non-stimulants are great options.

The hare and the tortoise: How fast do they kick in?

This is one of the most under appreciated practical differences.

Stimulants work within 30–60 minutes of the first dose (the hare). You can see whether they're helping by the end of the school day. Dose adjustments can happen weekly, sometimes daily which allows us to pivot quickly to find the right stimulant at the right dose, without loosing too much time.

Non-stimulants need weeks (the tortoise). Atomoxetine's median time to first noticeable response is around 23 days, with the response continuing to build out to 6–9 weeks¹¹. 

Qelbree is a bit faster and improvements have been seen as early as week one at the 100mg+ doses⁴.

Guanfacine and clonidine require a careful 4–7 week introduction titration because of their blood-pressure effects¹².

If a child is failing school, melting down daily, or otherwise in crisis, the delay of a non-stimulant is a real disadvantage if you need something that works quickly.

If you have time and patience and want to avoid stimulant side effects, then the non-stimulants may be the first choice.

Side effects: Common in both medications

In terms of side effects, it is not overly clear that non-stimulants are more ‘side effect light’ than stimulants.

I’ve encountered families for whom we have had to stop the non-stimulant because a child was having such problematic side effects, with for example, atomoxetine or qelbree. On stimulants they had no side effects and visa versa for different families.

Here, below, is a brief summary of the most typical side effects for each, and as you will notice the non-stimulants do not necessarily have 'more favorable' side effects than stimulants.

Stimulants 

• Insomnia / delayed sleep onset. Stimulants push out the time it takes to get to sleep by 30–40 minutes on average¹⁵.

• Decreased appetite. Around 28% of kids on stimulants in trials¹³, but in real-world practice closer to 80%, experience some appetite suppression, although it usually lessens over the first 6 months¹⁴. Front-loading calories at breakfast and again at dinner when the medication wears off is the standard workaround.

• Headaches, dry mouth, abdominal pain.

• Emotional lability and “rebound.” As the drug wears off in the late afternoon, kids can temporarily get worse than baseline and become irritable, weepy, and hyperactive. This is one reason long-acting formulations are preferred.

• Tics. Older labeling warned against stimulants in kids with tics, but a meta-analysis of 22 placebo-controlled trials (n=2,385) found stimulants don't worsen tics at the group level. (New or worsening tics occurred in 5.7% of kids on stimulants vs. 6.5% on placebo¹⁶.) The risk was unaffected by stimulant type, dose, or duration. Even in kids who already have tics, controlled trials show methylphenidate doesn't make them worse on average, though high doses can still provoke tics in individual children.

  
  

Non-stimulants

• Sleepiness. This is the headline issue. About 34% of kids on non-stimulants report somnolence vs. about 4% on stimulants¹³. Guanfacine is famously sedating in the first 2–3 weeks. Qelbree's label explicitly warns about driving and operating machinery¹⁷.

• Atomoxetine and viloxazine carry an FDA black box warning for suicidal ideation in pediatric patients. In qelbree's pediatric trials, 0.9% of kids reported suicidal ideation or behavior vs. 0.4% on placebo¹⁸. No completed suicides occurred, but close monitoring is recommended, especially in the first few months.

• Nausea, fatigue, irritability with atomoxetine and qelbree.

• Hypotension, bradycardia, and dizziness with guanafcine and clonidine. About 1% of kids on guanfacine experience dizziness when standing, or fainting¹². Abrupt discontinuation can cause rebound hypertension so these meds must be tapered, never stopped cold.

Stimulants, notably, do not carry the suicidality black box warning, but they are Schedule II controlled substances with abuse potential.

So as you can see both families of ADHD medication have side effects, and one set of side effects is not necessarily ‘better’ of 'more gentle' than the other.

Which is easiest to get a hold of at the pharmacy?

Access can be a problem and in some cases, the deciding factor when waiting weeks for an out-of-stock stimulant medication is not an option.

While both require a prescription, stimulants and non stimulants sit in entirely different categories when it comes to supply chains, regulations, and inventory.

These difference usually come down to the following reasons:

1) Controlled Substance Regulations

Stimulants (like methylphenidate or amphetamine-based medications) are classified as Schedule II controlled substances.

Because of this, they are subject to strict federal production quotas, rigid dispensing laws, no refills without a new prescription, and tight security protocols at the pharmacy. This can lead to delays in securing the prescription for a child.

Non-stimulants (like atomoxetine, guanfacine, or clonidine) are not controlled substances. Pharmacies can stock them freely, reorder them without regulatory red tape, and process multi-month refills smoothly, so they are 'easier' to find at the pharmacy without long delays.

2) Supply Chain Dynamics & Shortages

The pharmaceutical industry has faced prolonged, widespread shortages of stimulant medications.

Because manufacturing quotas are strictly capped by regulatory bodies, manufacturers cannot easily bump up extra production to meet sudden spikes in demand. Non-stimulants rarely face these systemic, long-term supply chain bottlenecks.

3) Pharmacy Inventory Verification

If a specific pharmacy runs out of a medication:

• For a non-stimulant, a pharmacist can easily look at their system, check if a sister location has it, or simply order it to arrive on the next standard delivery truck (usually within 24–48 hours).

  
  

• For a stimulant, inventory systems are often kept under tight wraps for security reasons. Pharmacists are often restricted from checking stock at other locations over the computer, meaning patients or providers frequently have to call multiple pharmacies individually to locate a specific dose. This is frustrating for medical providers and families.

  
  

Because of these layers of regulation and the ongoing supply strain on controlled medications, non-stimulants are much more predictable and readily available on pharmacy shelves which can, but not always, influence whether a family starts with a stimulant or a non stimulant medication for any given child.

When non-stimulants become first-line

For “plain vanilla” ADHD in a school-aged child, stimulants are first-line per national and international guidelines.

But here's where the choice can flip:

• Significant tic disorder or Tourette's: Alpha-2 agonists (guanfacine, clonidine) have “Level B” evidence for treating both tics and ADHD with one medication²⁷.

• Severe anxiety alongside ADHD: Atomoxetine and viloxazine, being noradrenergic (and qelbree also serotonergic), tend to play more nicely with a child's nervous system than stimulants. Stimulants can amplify anxiety, jitteriness, and panic-like symptoms in vulnerable kids²⁸.

• Active substance use disorder in an adolescent: Stimulants are Schedule II controlled substances with abuse and diversion potential. Atomoxetine, qelbree, and guanfacine have very low abuse potential and are the clear choice here²⁹.

• Severe insomnia or oppositional aggression: The sedating profile of clonidine and guanfacine can help.

Preschoolers (ages 4–5) are a special case

The AAP is firm: behavior therapy first, for kids ages 4 to 5. Medication only enters the picture if behavior therapy fails and the child has moderate-to-severe ongoing impairment². 

If medication is needed, methylphenidate is the only stimulant with explicit guideline support in this age group.

Preschoolers do respond to stimulants (about 82% response rate)³¹ but suffer dramatically more side effects than older kids, like emotional flatness, irritability, clinginess, and appetite suppression³².

In this age group, clonidine are often used off-label. Compared to stimulants, preschoolers on guanfacine or clonidine have markedly lower rates of moodiness (29% vs. 50%), appetite suppression (7% vs. 38%), and sleep trouble (11% vs. 21%)³³. The tradeoff is daytime sleepiness, which occurs in about 38% on alpha-2 agonists vs. only 3% on stimulants³³.

Combination therapy

It's not unusual to end up on more than one ADHD medication.

About 10.5% of kids being treated for ADHD are on a combination regimen³⁴.

The most common pairing is a long-acting morning stimulant plus an evening dose of an alpha-2 agonist like clonidine or guanfacine. The stimulant covers the school day, and the alpha-2 agonist smooths out the late-afternoon rebound and helps with sleep onset.

Formulation matters more than people think

Using once-daily long-acting formulations means that a child is more likely to stick to the regimen and take their medications daily, compared to immediate-release multi-dose regimens³⁵ which have to be taken 2-3 times per day to provide the same whole day coverage. This is because kids hate going to the school nurse mid-day. Stigma is real.

Another thing to mention is that with stimulant medication, 'stimulant holidays' can be taken, which means that stimulants can be used only 'as needed' for school, Monday to Friday, with weekends off the medication, or even school holidays off (under medical supervision). This flexibility is very attractive for some families who do not feel comfortable with their children taking a medication every-single-day.

Non-stimulants, by comparison, need to be taken every day and doses should not be skipped, otherwise we risk with-drawl symptoms and loss of medication effectiveness resulting in break through symptoms.

A few honest takeaways when considering stimulants vs non stimulants

A few things that get glossed over in clinical encounters but are worth knowing:

1. The starting medication selected can depend on 'what else' is going on with a child.  A reasonable starting point for uncomplicated ADHD in a school-aged child is a long-acting stimulant. A reasonable starting point in a kid with tics, severe anxiety, or substance use issues is a non-stimulant.

2. Both medication families have side effects. Stimulants do not have 'worse' side effects and non stimulants do not have 'better' side effects.

3. Stimulants are considered more effective than non stimulants. But that doesnt matter if a child is unable or unwilling to take a stimulant, for whatever reason. Here the non-stimulants are still excellent options.

4. Non stimulants are easier to find. Pharmacies typically carry both, but sometimes there are delays in securing a stimulant medication, so you may not end up starting the medication as soon as you would have liked too.

5. Stimulants are more 'flexible'. Stimulants can essentially be used 'as needed' (under medical supervision). Non-stimulants need to be taken daily to remain effective.

This site is for general informational purposes only and does not constitute the giving of medical advice. The contents do not constitute the practice of medicine, nursing, or other professional health care services. No provider–patient relationship is formed. Please consult with your child's healthcare provider when considering treatment interventions for children.

References

¹ Cortese, S. et al. (2018). Comparative efficacy and tolerability of medications for ADHD. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/30097390/

² American Academy of Pediatrics ADHD Clinical Practice Guideline. https://publications.aap.org/pediatrics/article/128/5/1007/31018/

³ Faraone, S. V. (2018). The pharmacology of amphetamine and methylphenidate. Neurosci Biobehav Rev. https://pmc.ncbi.nlm.nih.gov/articles/PMC6109107/

⁴ Viloxazine ER review. Expert Review of Neurotherapeutics. https://www.tandfonline.com/doi/full/10.1080/14737175.2024.2327533

⁵ Role of Alpha-2 Agonists in ADHD. https://pmc.ncbi.nlm.nih.gov/articles/PMC10204383/

⁶ Cortese et al. (2018), as above.

⁷ SPN-812 Phase II Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC6939319/

⁸ Rethinking First-Line ADHD Medication. ADHD Evidence Project. https://www.adhdevidence.org/blog/rethinking-first-line-adhd-medication-are-non-stimulants-being-undervalued

⁹ Comparative efficacy and safety of ADHD pharmacotherapies (Mixed Treatment Comparison). https://pmc.ncbi.nlm.nih.gov/articles/PMC5532417/

¹⁰ Research Review: Medications for ADHD. ADDitude Magazine. https://www.additudemag.com/medications-for-adhd-research-review/

¹¹ Atomoxetine response timeline. Käypä hoito. https://www.kaypahoito.fi/nak06057

¹² Guanfacine (Intuniv) for ADHD. American Family Physician. https://www.aafp.org/afp/2011/0215/p468

¹³ Long-Acting Stimulant vs Nonstimulant Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/29897263/

¹⁴ ADHD Medications for Children: Side Effects. ADDitude. https://www.additudemag.com/adhd-medications-for-children/

¹⁵ Stimulant medications and sleep disruption. 2 Minute Medicine. https://www.2minutemedicine.com/stimulant-medications-for-adhd-linked-to-sleep-disruption/

¹⁶ Pharmacological treatment for ADHD with comorbid tic disorders. https://pmc.ncbi.nlm.nih.gov/articles/PMC6513283/

¹⁷ Qelbree (Viloxazine) FDA Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf

¹⁸ Extended-Release Viloxazine for Children and Adolescents. https://pmc.ncbi.nlm.nih.gov/articles/PMC9268104/

¹⁹ MTA 16-year Growth Trajectory Study. https://pmc.ncbi.nlm.nih.gov/articles/PMC7021562/

²⁰ ADHD stimulants and height in children. https://pmc.ncbi.nlm.nih.gov/articles/PMC2821235/

²¹ Non-Stimulant Medications for ADHD. Lurie Children's. https://ramp.luriechildrens.org/en/conditions-and-treatments/medications/non-stimulants-for-adhd/

²² Extended-Release Stimulant Medication on Sleep. CACAP. https://cacap-acpea.org/wp-content/uploads/The-Effects-of-Extended-Release-Stimulant-Medication-on-Sleep.pdf

²³ Sleep and ADHD Medication Use: Clinician's Guide. ADDitude. https://www.additudemag.com/sleep-and-adhd-medication-side-effects-children/

²⁴ Farhat, L. et al. (2025). Comparative cardiovascular safety of ADHD medications. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/40203844/

²⁵ Cardiovascular Effects of Stimulant and Non-Stimulant Medication. https://pmc.ncbi.nlm.nih.gov/articles/PMC5336546/

²⁶ Most ADHD meds affect BP and pulse. Epocrates / Science Media Centre. https://www.epocrates.com/online/article/most-adhd-meds-not-just-stimulants-can-have-modest-effects-on-bp-and-pulse

²⁷ ADHD and Comorbidities Management Principles. Psych Scene Hub. https://psychscenehub.com/psychinsights/adhd-and-comorbidities-management-principles/

²⁸ Pharmacotherapy of ADHD in Young Children. https://pmc.ncbi.nlm.nih.gov/articles/PMC2957280/

²⁹ Challenges of Treating ADHD with Comorbid Substance Use. https://pmc.ncbi.nlm.nih.gov/articles/PMC10179386/

³⁰ International Consensus Statement on ADHD. ADHD Evidence Project. https://www.adhdevidence.org/evidence

³¹ Naturalistic stimulant treatment in young children. https://pmc.ncbi.nlm.nih.gov/articles/PMC2957280/

³² Pharmacotherapy of ADHD in Young Children, as above.

³³ Preschool ADHD medication side effects comparison. Boston Children's Hospital. https://answers.childrenshospital.org/preschool-adhd-medications/

³⁴ Combination Therapy in ADHD. HMP Global Learning Network. https://www.hmpgloballearningnetwork.com/site/pcn/blog/combination-therapy-adhd-when-and-how-augment-treatment-safely

³⁵ Compliance, Efficacy, and Satisfaction comparison of stimulants vs non-stimulants. https://pmc.ncbi.nlm.nih.gov/articles/PMC7788668/